Zomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: NASDAQ.COM
Zomedica Corp. Earnings Report: Zomedica reported a quarterly loss of $0.02 per share, missing the consensus estimate of a loss of $0.01, and has not surpassed EPS or revenue estimates in the last four quarters. The company's revenues for the quarter were $6.5 million, falling short of expectations by 16.45%.
Stock Performance Outlook: Zomedica shares have declined by approximately 51.6% this year, while the broader market has seen slight gains. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market, as investors await changes in earnings estimates following the recent report.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 82.540
Low
73.00
Averages
90.33
High
100.00
Current: 82.540
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
